Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Operating Income

Profit from core operations after operating expenses, before interest and taxes.

No reported Operating Income figures are available to summarize.

Operating Income history

Currency unavailable · from the income statement

No Operating Income data reported for this period type.

Operating Income vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Operating Income for KARD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IKTInhibikase Therapeutics, Inc.LTM Mar 2026-$55.59M USD-44.8%——
RNAAtrium Therapeutics, Inc.FY2025-$76.81M USD——412.6%
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$85.86M USD+21.8%—38159.1%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026-$244.41M USD-41.4%—3432.2%
CYTKCytokinetics, IncorporatedLTM Jun 2026-$704.62M USD-28.8%—993.0%
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —-35.1%—2212.6%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.